

William Gradishar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3722995/publications.pdf>

Version: 2024-02-01

27
papers

448
citations

933447

10
h-index

713466

21
g-index

28
all docs

28
docs citations

28
times ranked

929
citing authors

#	ARTICLE	IF	CITATIONS
1	Social cognitive variables and physical activity during chemotherapy for breast cancer: An intensive longitudinal examination. <i>Psycho-Oncology</i> , 2022, 31, 425-435.	2.3	8
2	Study design and protocol for tailored Acceptance and Commitment Therapy (ACT) to optimize quality of life in women living with metastatic breast cancer. <i>Contemporary Clinical Trials Communications</i> , 2022, 25, 100870.	1.1	3
3	Abstract P2-02-05: Dynamic circulating tumor cell changes in enumeration and HER2 expression during systemic therapy for metastatic breast cancer. <i>Cancer Research</i> , 2022, 82, P2-02-05-P2-02-05.	0.9	0
4	Abstract P2-01-04: Esr1 hotspot mutations in circulating tumor DNA mutation are associated with endocrine therapy resistance in metastatic breast cancer. <i>Cancer Research</i> , 2022, 82, P2-01-04-P2-01-04.	0.9	0
5	Abstract P2-01-08: <i>Esr1</i> Y537 mutations are associated with increased baseline circulating tumor cells enumeration for patients with estrogen receptor positive metastatic breast cancer. <i>Cancer Research</i> , 2022, 82, P2-01-08-P2-01-08.	0.9	0
6	Ductal Carcinoma In Situ of Breast: From Molecular Etiology to Therapeutic Management. <i>Endocrinology</i> , 2022, 163, .	2.8	5
7	Using ecological momentary assessment to understand associations between daily physical activity and symptoms in breast cancer patients undergoing chemotherapy. <i>Supportive Care in Cancer</i> , 2022, 30, 6613-6622.	2.2	2
8	Genomic Landscape of Advanced Solid Tumors in Circulating Tumor DNA and Correlation With Tissue Sequencing: A Single Institution's Experience. <i>JCO Precision Oncology</i> , 2022, , .	3.0	9
9	A Technology-Based Physical Activity Intervention for Patients With Metastatic Breast Cancer (Fit2ThriveMB): Protocol for a Randomized Controlled Trial. <i>JMIR Research Protocols</i> , 2021, 10, e24254.	1.0	3
10	Reply to S. Sorscher. <i>Journal of Clinical Oncology</i> , 2021, 39, 1188-1189.	1.6	1
11	Targeted eHealth Intervention to Reduce Breast Cancer Survivors'™ Fear of Recurrence: Results From the FoRtitude Randomized Trial. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1495-1505.	6.3	32
12	Evaluation of the Novel 4R Oncology Care Planning Model in Breast Cancer: Impact on Patient Self-Management and Care Delivery in Safety-Net and Non-Safety-Net Centers. <i>JCO Oncology Practice</i> , 2021, 17, e1202-e1214.	2.9	2
13	Daily Physical Activity and Symptom Reporting in Breast Cancer Patients Undergoing Chemotherapy: An Intensive Longitudinal Examination. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 2608-2616.	2.5	12
14	Addressing Fertility: an Essential Aspect of Comprehensive Care for Young Patients with Breast Cancer. <i>Current Breast Cancer Reports</i> , 2020, 12, 381-390.	1.0	1
15	Feasibility and acceptability of intensive longitudinal data collection of activity and patient-reported outcomes during chemotherapy for breast cancer. <i>Quality of Life Research</i> , 2019, 28, 3333-3346.	3.1	19
16	Are Biosimilars the Future of Oncology and Haematology?. <i>Drugs</i> , 2019, 79, 1609-1624.	10.9	10
17	Innovating Cancer Care Delivery: the Example of the 4R Oncology Model for Colorectal Cancer Patients. <i>Current Treatment Options in Oncology</i> , 2019, 20, 11.	3.0	3
18	The National Physicians Cooperative: transforming fertility management in the cancer setting and beyond. <i>Future Oncology</i> , 2018, 14, 3059-3072.	2.4	30

#	ARTICLE	IF	CITATIONS
19	Clinical Variant Classification: A Comparison of Public Databases and a Commercial Testing Laboratory. <i>Oncologist</i> , 2017, 22, 797-803.	3.7	40
20	Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Circulating Tumor DNA in Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1412-1420.	4.1	114
21	In Reply. <i>Oncologist</i> , 2017, 22, 1540-1540.	3.7	0
22	Association of <i>BRCA1</i> Mutations with Impaired Ovarian Reserve: Connection Between Infertility and Breast/Ovarian Cancer Risk. <i>Journal of Adolescent and Young Adult Oncology</i> , 2016, 5, 337-343.	1.3	53
23	Oncologists'™ Role in Patient Fertility Care. <i>JAMA Oncology</i> , 2016, 2, 171.	7.1	18
24	Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance). <i>Journal of the National Cancer Institute</i> , 2015, 107, .	6.3	52
25	Management of advanced breast cancer with the epothilone B analog, ixabepilone. <i>Drug Design, Development and Therapy</i> , 2009, 3, 163.	4.3	9
26	Landmark trials in endocrine adjuvant therapy for breast carcinoma. <i>Cancer</i> , 2006, 106, 975-981.	4.1	16
27	Fulvestrant in the treatment of postmenopausal women with advanced breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2005, 5, 445-453.	2.4	6